Literature DB >> 30450297

Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

Paul Halford1, Amelia O Clive2.   

Abstract

Malignant pleural mesothelioma has a high morbidity and poor prognosis. Most patients undergo invasive pleural interventions to either facilitate diagnosis and/or alleviate symptoms from malignant pleural effusion. Procedure tract metastasis (PTM) are a well-known complication of pleural procedures in mesothelioma and there has been longstanding debate regarding the role of prophylactic irradiation of tracts in preventing them. This review summarises the existing evidence surrounding this controversial topic. Despite initial discrepancies amongst the results of 3 small, historical trials regarding the efficacy of prophylactic radiotherapy in mesothelioma, two large randomised-control trials have recently provided more clarity. The SMART trial, which randomised over 200 patients, found no benefit of prophylactic radiotherapy in reducing PTM incidence in their primary analysis, with a number needed to treat (NNT) of 25.1 to prevent a single painful PTM. Additionally, there was no benefit in terms of symptomology, health-related quality of life parameters or cost-effectiveness. This is supported by the preliminary results of the Prophylactic Irradiation of Tracts in Patients with Pleural Mesothelioma (PIT) trial, which randomised 375 patients and also found no evidence that prophylactic radiotherapy reduced PTM incidence, although the full results are still awaited. Combined analysis of these trials is planned, which will help clarify whether specific subpopulations may derive benefit from prophylactic radiotherapy, such as patients not receiving chemotherapy. Based on the currently available evidence there is no role for routine delivery of prophylactic radiotherapy to prevent PTM in mesothelioma. Instead holistic and vigilant follow-up of patients is recommended, aiming for adequate palliation of symptoms and support for patients. Should painful nodules develop these can be effectively treated with subsequent palliative radiotherapy. After years of uncertainty and debate, recent international guidelines have consistently advised against the use of prophylactic irradiation of tracts based on contemporary high-quality evidence.

Entities:  

Keywords:  Mesothelioma; irradiation; metastasis; prophylactic radiotherapy

Year:  2018        PMID: 30450297      PMCID: PMC6204410          DOI: 10.21037/tlcr.2018.07.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  28 in total

1.  NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Authors:  David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Thomas Dilling; Michael Dobelbower; Ramaswamy Govindan; Mark Hennon; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; Neelesh Sharma; Scott J Swanson; James Stevenson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2016-07       Impact factor: 11.908

2.  Radiation sensitivity of human lung cancer cell lines.

Authors:  J Carmichael; W G Degraff; J Gamson; D Russo; A F Gazdar; M L Levitt; J D Minna; J B Mitchell
Journal:  Eur J Cancer Clin Oncol       Date:  1989-03

3.  Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy.

Authors:  Prachi P Agarwal; Jean M Seely; Fred R Matzinger; Robert M MacRae; Rebecca A Peterson; Donna E Maziak; Carole J Dennie
Journal:  Radiology       Date:  2006-09-27       Impact factor: 11.105

4.  Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.

Authors:  Piero Borasio; Alfredo Berruti; Andrea Billé; Paolo Lausi; Matteo Giaj Levra; Roberto Giardino; Francesco Ardissone
Journal:  Eur J Cardiothorac Surg       Date:  2008-02       Impact factor: 4.191

Review 5.  Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.

Authors:  Helen E Davies; Arthur W Musk; Y C Gary Lee
Journal:  Curr Opin Pulm Med       Date:  2008-07       Impact factor: 3.155

6.  A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.

Authors:  Noelle O'Rourke; Jose Curto Garcia; Jim Paul; Claire Lawless; Rhona McMenemin; Jennifer Hill
Journal:  Radiother Oncol       Date:  2007-06-22       Impact factor: 6.280

7.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.

Authors:  C Boutin; F Rey; J R Viallat
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

8.  Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

Authors:  Muzaffer Metintas; Guntulu Ak; Sebnem Parspour; Huseyin Yildirim; Sinan Erginel; Fusun Alatas; Hasan F Batirel; Cumhur Sivrikoz; Selma Metintas; Emine Dundar
Journal:  Lung Cancer       Date:  2008-03-04       Impact factor: 5.705

9.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Authors:  Karl Claxton; Steve Martin; Marta Soares; Nigel Rice; Eldon Spackman; Sebastian Hinde; Nancy Devlin; Peter C Smith; Mark Sculpher
Journal:  Health Technol Assess       Date:  2015-02       Impact factor: 4.014

10.  A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma.

Authors:  S Bydder; M Phillips; D J Joseph; F Cameron; N A Spry; Y DeMelker; A W Musk
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.